Clinical Genetics in Interstitial Lung Disease.

Area of Science:

• Pulmonology and Genetics
• Focuses on interstitial lung diseases (ILDs) with an emphasis on genetic underpinnings.

Background:

• Interstitial lung disease (ILD) is a diverse group of lung disorders with significant overlap in presentation.
• Idiopathic pulmonary fibrosis (IPF) and chronic hypersensitivity pneumonitis (CHP) are common and severe forms of ILD.
• Current diagnostic and treatment approaches for IPF and CHP show considerable variability, impacting patient outcomes.

Purpose of the Study:

• To review recent advancements in understanding the genomic factors influencing susceptibility and outcome risk in IPF and CHP.
• To highlight how genomic technologies can improve risk stratification and clinical decision-making for ILD patients.
• To identify knowledge gaps for integrating genomic insights into clinical practice.

Main Methods:

• Genome-wide association studies (GWAS)
• Gene expression analysis
• Drug-gene interaction testing
• Telomere length and telomerase mutation analysis
• Lung microbiome studies

Main Results:

• Genomic technologies are revealing key factors that affect IPF and CHP susceptibility and disease progression.
• These advances offer potential for more precise patient stratification and personalized therapeutic strategies.
• Significant variability in diagnosis, treatment response, and natural history persists across ILD subtypes.

Conclusions:

• Genomic insights are crucial for understanding the heterogeneity of IPF and CHP.
• Incorporating genomic markers into clinical practice can enhance ILD risk assessment and treatment personalization.
• Further research is needed to bridge the gap between genomic discoveries and routine clinical application in ILD management.